Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
9.6M
-
Shares change
-
+473K
-
Total reported value, excl. options
-
$482M
-
Value change
-
+$24.1M
-
Number of buys
-
44
-
Number of sells
-
-17
-
Price
-
$49.76
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q2 2018
65 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q2 2018.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.6M shares
of 46.2M outstanding shares and own 20.77% of the company stock.
Largest 10 shareholders include MENORA MIVTACHIM HOLDINGS LTD. (2.5M shares), Consonance Capital Management LP (1.49M shares), WELLINGTON MANAGEMENT GROUP LLP (987K shares), ProQuest Associates IV LLC (789K shares), FMR LLC (707K shares), MEITAV DASH INVESTMENTS LTD (509K shares), HIGHLINE CAPITAL MANAGEMENT, L.P. (332K shares), CITADEL ADVISORS LLC (321K shares), Clal Insurance Enterprises Holdings Ltd (310K shares), and CREDIT SUISSE AG/ (274K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.